U.S. Congress legislation · 119th Congress
SB5571: Biosimilars Access and Affordability Act
Status: In committee, September 28, 2026
A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
What the bill says
To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
From the introduced text, September 28, 2026:
A BILL To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program. SECTION 1. Short title This Act may be cited as the Biosimilars Access and Affordability Act . SECTION 2. Change of when biosimilars are eligible for price negotiations (a) In general Section 1192 of the Social Security Act ( 42 U.S.C. 1320f-1 ) is amended-- (1) in subsection (c)-- (A) in paragraph (1), in the matter preceding subparagraph (A), by striking such year and each subsequent year beginning before the first year that begins at least 9 months and inserting the year of the selected drug publication date for such initial price applicability year and each subsequent year, except that a drug or biological product shall no longer be a selected drug beginning on the first day of the year that begins ; and (B) in paragraph (2)-- (i) in subparagraph (B), by striking or during the negotiation period with respect to such initial price applicability year and inserting the first day of such initial price applicability year ; and (ii) in the flush text following subparagraph (B)-- (I) by striking and shall continue to and inserting if such negotiation period has not yet ended, shall not have its maximum fair price or the …
Sponsors
- Blackburn, Marsha (R) · primary sponsor
- Schiff, Adam B. (D)
- Lankford, James (R, SD-OK)
- Budd, Ted (R)
Latest actions
- : Read twice and referred to the Committee on Finance.
- : Introduced in Senate
Subjects: Health
Common questions
- What is SB5571?
- SB5571 is a bill in Congress (119th Congress): Biosimilars Access and Affordability Act.
- What does SB5571 do?
- In its own words: To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
- What is the status of SB5571?
- In committee as of September 28, 2026. Latest action: Read twice and referred to the Committee on Finance. (September 28, 2026).
- Who sponsored SB5571?
- Blackburn, Marsha (R), with 3 co-sponsors.
- Where is the official record for SB5571?
- On the Congress website: https://www.congress.gov/bill/119th-congress/senate-bill/5571
Source: official Congress record. Tracked by Delilah, AI for legislation across all 50 states and Congress.